Corcept CFO acquires 138 shares in equity plan

CORCEPT THERAPEUTICS INC (CORT) reported that its Chief Financial Officer, Atabak Mokari, had routine equity-related transactions.

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) reported that its Chief Financial Officer, Atabak Mokari, had routine equity-related transactions. On September 1, 2026, he acquired 138 shares of common stock under a purchase plan at a price based on the closing price that day and also received 138 shares underlying unvested restricted stock awards that will vest after one year if he remains the beneficial owner of the purchase-plan shares. On September 2, 2026, 102 shares of common stock were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units; no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Mokari Atabak

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F5, F6, F7	102	$113.38	$12K
Grant/Award	Common Stock F1, F2, F3	138	$113.38	$16K
Grant/Award	Common Stock F4, F3	138	$0.00	$0.00

Holdings After Transaction: Common Stock — 16,304 shares (Direct)

Footnotes (7)

1. F1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
2. F2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
3. F3. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
4. F4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
5. F5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
6. F6. The closing price on September 1, 2026 was used to calculate the withholding obligation.
7. F7. Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Key Figures

Shares purchased under purchase plan: 138 shares Purchase-plan reference price: $113.38 per share Unvested restricted shares granted (purchase-plan related): 138 shares +2 more

5 metrics

Shares purchased under purchase plan 138 shares Common stock acquired on September 1, 2026 under the purchase plan

Purchase-plan reference price $113.38 per share Price based on closing price on September 1, 2026 for purchase-plan shares

Unvested restricted shares granted (purchase-plan related) 138 shares Restricted stock awards granted on September 1, 2026, vesting after one year if conditions are met

Shares withheld for tax obligations 102 shares Common stock withheld on September 2, 2026 to satisfy tax withholding from RSU vesting

Unvested restricted stock from prior grants 1,409 shares 200 + 178 + 397 + 634 shares from grants in 2025 and 2026, vesting 100% after one year if requirements are satisfied

Key Terms

restricted stock awards, restricted stock units, purchase plan, beneficial owner

4 terms

restricted stock awards financial

"Includes 200 shares underlying unvested restricted stock awards granted"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

restricted stock units financial

"tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

purchase plan financial

"pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan"

beneficial owner financial

"provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

FAQ

What insider transactions did Corcept Therapeutics (CORT) report for its CFO?

Corcept Therapeutics reported that CFO Atabak Mokari acquired 138 shares of common stock under a purchase plan and received 138 unvested restricted shares on September 1, 2026, and had 102 shares withheld on September 2, 2026 for tax obligations tied to vesting restricted stock units.

Were the recent CORT insider transactions open-market buys or sells?

No. The filing shows no open-market purchases or sales. Shares were acquired through a purchase plan and as restricted stock awards, and 102 shares were withheld by the issuer to cover tax withholding obligations from vesting restricted stock units.

How many Corcept Therapeutics (CORT) shares were withheld for the CFO’s taxes?

The issuer withheld 102 shares of Corcept Therapeutics common stock on September 2, 2026 to satisfy tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

What price was used for the Corcept Therapeutics (CORT) CFO’s purchase-plan shares?

For the 138 shares purchased under the purchase plan on September 1, 2026, the price was established based on the closing price on the day of the purchase, as specified in the purchase plan.

What are the vesting conditions for the CORT CFO’s recent restricted stock awards?

The filing states that 100% of the shares underlying the relevant restricted stock awards will vest on the one-year anniversary of the grant date, provided that Atabak Mokari meets specified requirements, including remaining the beneficial owner of the purchase-plan shares for certain awards.

Were the Corcept Therapeutics (CORT) CFO’s transactions under a Rule 10b5-1 plan?

No. The Rule 10b5-1 checkbox is not marked as being used for these transactions, and the footnotes describe purchases under a purchase plan and tax withholding, but do not state that a Rule 10b5-1 trading plan governed them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 09:07 PM Accepted by SEC EDGAR 09/03/2026 - 09:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mokari Atabak

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		A		138(1)	A	$113.38(2)	16,268(3)	D
Common Stock	09/01/2026		A		138(4)	A	$0.00	16,406(3)	D
Common Stock	09/02/2026		F(5)		102	D	$113.38(6)	16,304(7)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

6. The closing price on September 1, 2026 was used to calculate the withholding obligation.

7. Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)